ClinicalTrials.gg
CompletedNCT05661006ETOL-ElderlyUpdated Jun 22, 2023

ETOL-Elderly Study of the Efficiency of the Innovative Food Supplement in Elderly Adults

An interventional study of Use of food supplement and Use of placebo food supplement in Vitamin d Deficiency, Vitamin B 12 Deficiency and Protein Deficiency, sponsored by Nutrition Institute, Slovenia. Completed at 1 site in Slovenia. Open to participants aged 65 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Nutrition Institute, Slovenia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Feb 2020, registered Dec 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
65 Years to 95 Years
Sex
All
01

Study summary

The aim of this pilot study is to conduct a study on geriatric population in Slovenia (non-users of dietary supplements/medicines with vitamine D, vitamin B12 and protein) and assess deficiency of selected nutrients, and to investigate the efficiency of the innovative food supplement prototype in improving nutritional status of elderly adults.

Read the detailed description

The main objective is to show that in the geriatric population regular use of investigation food supplement would improve nutritional status. The study should provide answers to the following main questions: (1) Is regular use of investigated product beneficial for improving serum vitamin D levels in elderly population? (2) Is regular use of investigated product beneficial for increasing daily protein intake in elderly population? (3) Is regular use of investigated product beneficial for improving vitamin B12 status in elderly population?

02

Conditions studied

  • Vitamin d Deficiency
  • Vitamin B 12 Deficiency
  • Protein Deficiency
03

In context

Vitamin D Deficiency

801 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

This study's enrollment of 40 is below the median of 78 across 590 interventional studies indexed under Vitamin D Deficiency.

Browse Vitamin D Deficiency studies →

Lead sponsor

Nutrition Institute, Slovenia is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject form (ICF) is singed
  • Aged at least 65 at the time of the signature of ICF
  • A lower than 32 kg/m2
  • Willing to avoid a consumption supplementation with protein, vitamin D and vitamin B12 during the study
  • Willing to follow all study procedures, including attending all site visits (including blood sampling) and keeping a diary for using the product and six 24-hour dietary records (3x pre-intervention, 3x during last week of the intervention)

Exclusion criteria

Exclusion criteria:

  • Medical treatment with Vitamin D and/or Vitamin B12
  • Supplementation with protein, vitamin D and/or vitamin B12 during least 2 months
  • Known drug and/or alcohol abuse
  • Known lactose/gluten intolerances/food allergies
  • Inadequate veins (in the opinion of the investigator) or known for venous blood withdrawal
  • Have chronic bowel disease (ulcerative colitis, Chron's disease, stomach or duodenal ulcer, chronic inflammation of the stomach or duodenum)
  • Have acute gastrointestinal infection with vomiting and / or diarrhea
  • Have planned general anaesthesia or colonoscopy at the time of the study
  • Have malabsorption syndrome
  • Less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)
  • Have stomach or bowel resection
  • Do not have neat and functional teeth
  • Take regular or occasional laxative products
  • Use antacids (Rupurut / Rutacid / Talcit)
  • Mental incapacity that precludes adequate understanding or cooperation
  • Participation in another study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    Control group

    Subjects taking control product

    Dietary Supplement: Use of placebo food supplement

  • Experimental
    Active group

    Subjects taking active product

    Dietary Supplement: Use of food supplement

Interventions

  • Dietary supplementUse of food supplement

    On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day). Intervention end on day 56 ±3 (fasted condition): Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product

  • Dietary supplementUse of placebo food supplement

    On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end

06

What researchers measure

Primary outcomes

  1. Change in serum vitamin D levels will be determined

    Serum level of 25-OH-vitamin D will be measured before and after the intervention for each individual.

    Time frame: 56 days

Secondary outcomes

  1. Change in dietary protein intake will be determined

    Dietary protein intake will be estimated before and after the intervention for each individual, using 3x24h food records.

    Time frame: 56 days

  2. Change in serum vitamin B12 levels will be determined

    Serum level of vitamin B12 will be measured before and after the intervention for each individual.

    Time frame: 56 days

  3. Malnutrition at baseline

    Risks for malnutritition at baseline will be assessed using dietary records (3x24h food record: energy, protein and plasma concentration of 25-OH-D and vitamin B12.

    Time frame: baseline

07

Study locations

1 site
  • VIZERA
    Trzin, Slovenia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in May 2020, 2 months.

Of 168 non-industry interventional studies with no phase under Vitamin D Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 2 months is below that.

Counting every sponsor, half of 170 studies reached it within 11 months; a quarter within 4 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Dec 21, 2022
StartActual
Feb 20, 2020
Primary completionActual
May 5, 2020
CompletionActual
Jun 29, 2020
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05661006
Lead sponsor
Nutrition Institute, Slovenia
Collaborators
Vizera d.o.o., Frutarom Etol d.o.o., European Regional Development Fund
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Feb 20, 2020
Primary completion
May 5, 2020
Completion
Jun 29, 2020
Last update
Jun 22, 2023

Study contacts

Mojca Miholič, MD
principal investigator · Researcher

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion